The von Hippel-Lindau tumor suppressor(VHL)has been extensively used to develop degraders targeting numerous proteins of interest.However,studies on the rational design of VHL-proteolysis-targeting chimeras(PROTACs)re...The von Hippel-Lindau tumor suppressor(VHL)has been extensively used to develop degraders targeting numerous proteins of interest.However,studies on the rational design of VHL-proteolysis-targeting chimeras(PROTACs)remain scarce.This study aimed to develop strategies to investigate VHL-recruiting PROTACs connecting with varying attachment sites on VHL ligands,which could be utilized for KRAS^(G12C) degraders development and expanded to additional targets.We developed a molecular dynamics(MD)-based strategy to explore the stability of ternary complexes induced by KRAS^(G12C) PROTACs with four distinct attachment sites of VH032.We found a potent degrader namely YN14-H,linked to hydroxyl group on VH032 benzene ring,exhibited the most superior ability of inducing ternary complexes,reflected by the lowest dissociation constant(Kd)for ternary complex induction and the highest AlphaScreen(AS)-based interaction.YN14-H inhibited cell growth with low nanomolar half maximal inhibitory concentration(IC_(50))and half maximal degradation concentration(DC_(50))values as well as>98%of maximum degradation(D_(max))in NCI-H358 and MIA PaCa-2 cells harboring KRAS^(G12C)-mutation.Mechanistically,YN14-H significantly induced apoptosis and inhibited the migratory capacity.Notably,YN14-H demonstrated favorable pharmacokinetic properties and excellent antitumor activity in vivo.Furthermore,bromodomain-containing protein 7(BRD7)and Bruton tyrosine kinase(BTK)degraders attached to distinct sites on VH032 further verified the rationality and universality of our MD-based strategies.Our findings demonstrated that YN14-H could serve as a promising candidate for the treatment of tumors with KRAS^(G12C)-mutation and present a strategy for the rational design of VHL-recruiting PROTACs that target additional proteins at distinct attachment sites.展开更多
BACKGROUND Kirsten rat sarcoma viral oncogene homolog(KRAS)is a commonly identified oncogenic driver in solid tumors,especially in non-small cell lung cancer.Until recently,KRAS was believed to be impossible to target...BACKGROUND Kirsten rat sarcoma viral oncogene homolog(KRAS)is a commonly identified oncogenic driver in solid tumors,especially in non-small cell lung cancer.Until recently,KRAS was believed to be impossible to target because it lacks adenosine triphosphate-binding domains or other regions that allow specic small-molecule inhibitors to act.In this report,we described using KRAS at glycine 12 to cysteine(G12C)inhibitors as posterior line therapy in a patient with relapsed metastatic lung adenocarcinoma carrying KRAS G12C mutation.CASE SUMMARY A 53-year-old Chinese man was treated with radical surgical resection for lung cancer in June 2014.Re-examination in June 2015 indicated postoperative rec-urrence with metastasis.The patient completed several courses of antitumor therapy,including pemetrexed and nedaplatin,bevacizumab with docetaxel and cisplatin,bevacizumab and pemetrexed,sintilimab and anlotinib,sintilimab and albumin-bound paclitaxel,and cadonilimab and docetaxel.In early May 2023,the patient developed a cough productive of bloody sputum and shortness of breath after exercise.The main adverse reactions associated with KRAS G12C inhibitor therapy were gastrointestinal reactions,which could be alleviated by daily oral ondansetron tablets.CONCLUSION After multiple-line treatment including chemotherapy,targeted therapy,and immunotherapy,disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy,and the adverse reactions to the therapy were tolerable.展开更多
基金supported by National Natural Science Foundation of China(No.82404417)State Key Laboratory of National Security Specially Needed Medicines Program(No.LTMC2022Zz006).
文摘The von Hippel-Lindau tumor suppressor(VHL)has been extensively used to develop degraders targeting numerous proteins of interest.However,studies on the rational design of VHL-proteolysis-targeting chimeras(PROTACs)remain scarce.This study aimed to develop strategies to investigate VHL-recruiting PROTACs connecting with varying attachment sites on VHL ligands,which could be utilized for KRAS^(G12C) degraders development and expanded to additional targets.We developed a molecular dynamics(MD)-based strategy to explore the stability of ternary complexes induced by KRAS^(G12C) PROTACs with four distinct attachment sites of VH032.We found a potent degrader namely YN14-H,linked to hydroxyl group on VH032 benzene ring,exhibited the most superior ability of inducing ternary complexes,reflected by the lowest dissociation constant(Kd)for ternary complex induction and the highest AlphaScreen(AS)-based interaction.YN14-H inhibited cell growth with low nanomolar half maximal inhibitory concentration(IC_(50))and half maximal degradation concentration(DC_(50))values as well as>98%of maximum degradation(D_(max))in NCI-H358 and MIA PaCa-2 cells harboring KRAS^(G12C)-mutation.Mechanistically,YN14-H significantly induced apoptosis and inhibited the migratory capacity.Notably,YN14-H demonstrated favorable pharmacokinetic properties and excellent antitumor activity in vivo.Furthermore,bromodomain-containing protein 7(BRD7)and Bruton tyrosine kinase(BTK)degraders attached to distinct sites on VH032 further verified the rationality and universality of our MD-based strategies.Our findings demonstrated that YN14-H could serve as a promising candidate for the treatment of tumors with KRAS^(G12C)-mutation and present a strategy for the rational design of VHL-recruiting PROTACs that target additional proteins at distinct attachment sites.
基金Supported by National Natural Sciences Foundation of China,No.81803553.
文摘BACKGROUND Kirsten rat sarcoma viral oncogene homolog(KRAS)is a commonly identified oncogenic driver in solid tumors,especially in non-small cell lung cancer.Until recently,KRAS was believed to be impossible to target because it lacks adenosine triphosphate-binding domains or other regions that allow specic small-molecule inhibitors to act.In this report,we described using KRAS at glycine 12 to cysteine(G12C)inhibitors as posterior line therapy in a patient with relapsed metastatic lung adenocarcinoma carrying KRAS G12C mutation.CASE SUMMARY A 53-year-old Chinese man was treated with radical surgical resection for lung cancer in June 2014.Re-examination in June 2015 indicated postoperative rec-urrence with metastasis.The patient completed several courses of antitumor therapy,including pemetrexed and nedaplatin,bevacizumab with docetaxel and cisplatin,bevacizumab and pemetrexed,sintilimab and anlotinib,sintilimab and albumin-bound paclitaxel,and cadonilimab and docetaxel.In early May 2023,the patient developed a cough productive of bloody sputum and shortness of breath after exercise.The main adverse reactions associated with KRAS G12C inhibitor therapy were gastrointestinal reactions,which could be alleviated by daily oral ondansetron tablets.CONCLUSION After multiple-line treatment including chemotherapy,targeted therapy,and immunotherapy,disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy,and the adverse reactions to the therapy were tolerable.
